Juric SOLAR-1 alpelisib trial biomarker analysis. Alpelisib previously approved based on PFS improvement with PIK3CA mutant tumors. ITT and biomarker cohorts have similar PFS results. TMB does not alter outcomes. Altered FGFR1/2 do not affect alpelisib benefit. Altered Myc bad.